FDA approves cUTI combo Vabomere from MDCO

FDA approved Vabomere meropenem/vaborbactam (Carbavance) from The Medicines Co. (NASDAQ:MDCO) to treat adults with complicated urinary tract infections

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE